Medicenna's Participation at H.C. Wainwright's Conference
Medicenna Therapeutics Corp. (NASDAQ: MDNA) is set to make a mark at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The event takes place from September 8 to 10, bringing together thought leaders and innovators in the investment community.
Key Details About the Conference Presentation
Dr. Fahar Merchant, the President and CEO of Medicenna, will present to potential investors and engage in one-on-one meetings during the event. The conference will be held at the prestigious Lotte New York Palace Hotel, known for hosting significant financial discussions.
The specifics of Dr. Merchant's presentation are eagerly anticipated by stakeholders and enthusiasts in the biotechnology sector. It promises to showcase Medicenna's strategic plans and development efforts in cancer immunotherapy.
Presentation Schedule
The scheduled time for Dr. Merchant's presentation is on September 9, and it will occur from 2:30 PM to 3:00 PM Eastern Standard Time. Participants who wish to take part in the presentation can look forward to a thorough overview of the company’s innovations during this period.
Accessing the Live Webcast
For individuals who cannot attend in person, a webcast of the conference will be available. Viewers can find the webcast link on Medicenna’s official website. This initiative aligns with the company's commitment to transparency and accessibility for its investors and the public.
Impact of Medicenna's Innovations
Medicenna is paving the way for ground-breaking developments in the treatment of cancer through their focus on Superkines. Their lead product candidate, MDNA11, is designed to stimulate the immune system's T cells and NK cells effectively, offering an innovative approach to immune-oncology.
Furthermore, the company’s Empowered Superkine known as bizaxofusp has shown promise in multiple clinical trials. This approach specifically seeks to tackle recurring Glioblastoma Multiforme (GBM), a notoriously difficult form of brain cancer. With both FastTrack and Orphan Drug designations from the FDA, the treatment has gained attention for its potential to address this significant health challenge.
R&D Initiatives and Future Prospects
In addition to their lead candidates, Medicenna is exploring other options to strengthen its therapy portfolio. The introduction of their BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs speaks volumes about the company’s innovative spirit and commitment to advancing cancer treatment.
About Medicenna Therapeutics Corp.
Founded on the principles of innovation in cancer treatment, Medicenna has firmly established itself within the biotech industry. The company focuses on harnessing the potential of the immune system to combat cancer using differentiated therapies designed to maximize efficacy and minimize side effects.
Investor Relations Contact Information
Interested investors and media representatives can reach out to Shushu Feng, who handles investor relations for Medicenna. She can be contacted at (416) 964-5442 or via email. Stay updated on Medicenna’s advancements through their dedicated channels for investor relations.
Frequently Asked Questions
What is the H.C. Wainwright Global Investment Conference?
This conference is a significant event where companies engage with the investment community, presenting their projects and developments.
Where will the conference take place?
The event will be held at the Lotte New York Palace Hotel in New York City.
Who is presenting at the conference?
Dr. Fahar Merchant, the President and CEO of Medicenna, will make the presentation.
What is MDNA11?
MDNA11 is a next-generation IL-2 Superkine developed by Medicenna, aimed at improving cancer treatment outcomes.
How can I access Medicenna's presentation?
Those unable to attend can access a live webcast available on Medicenna’s website during the presentation.
